Loading clinical trials...

An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence | Clinical Trials | Clareo Health

RECRUITING

An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence

NCT06420219•University of Southern California

View on ClinicalTrials.gov

Summary

This study evaluates the cell and biomarkers associated with the aggressive behavior of cancer.

Detailed Description

PRIMARY OBJECTIVE: I. High-resolution single-cell profiling of Cancer-associated fibroblasts (CAFs) in Human papillomavirus (HPV)+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) and metastatic lymph nodes. OUTLINE: This is an observational study. Patients undergo photography, blood sample collection, tissue collection and have their medical records reviewed on study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis/disease status: New diagnosis of head and neck cancer
•Allowable type and amount of prior therapy: No prior treatment
•Age ≥ 18 years.
•Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria

•Patients who have had treatment of head and neck cancer

Locations (1)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Key Dates

Start Date

March 25, 2024

Primary Completion Date

March 25, 2028

Completion Date

March 25, 2029

Last Updated

January 16, 2026

Enrollment

ESTIMATED participants

Conditions

Head and Neck Carcinoma

Interventions

Non-Interventional Study

OTHER

Contacts

Sandy Tran, MS

CONTACT

323-865-0451 sandy.tran@med.usc.edu

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

NCT05526924

Head and Neck CancerHead and Neck Squamous Cell Carcinoma+3 more

View study

RECRUITINGPHASE2

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

NCT05075980

Head and Neck CarcinomaHead and Neck Carcinoma of Unknown Primary+10 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence

Inclusion Criteria

Exclusion Criteria

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy